Ver­tex backs out of agree­ment with CRISPR Ther­a­peu­tics for stem cell ther­a­py can­di­date in di­a­betes

Ver­tex Phar­ma­ceu­ti­cals’ sub­sidiary Vi­a­Cyte is back­ing out of one of its col­lab­o­ra­tions with CRISPR Ther­a­peu­tics on gene-edit­ed stem cell ther­a­pies for di­a­betes.

CRISPR said Mon­day that Vi­a­Cyte has de­cid­ed to opt-out of a co-de­vel­op­ment and co-com­mer­cial­iza­tion agree­ment for CTX211, its be­ta cell re­place­ment ther­a­py “that is trans­plant­ed in­to pa­tients in a de­vice and in­tend­ed to pro­duce in­sulin in a glu­cose-de­pen­dent man­ner.” While CRISPR in Feb­ru­ary will whol­ly own the can­di­date again, Vi­a­Cyte will be paid a roy­al­ty on fu­ture sales.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER